Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

1(10%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

10%

Ph phase_1

40%

Ph not_applicable

10%

Ph phase_2

30%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

1(11.1%)

N/ANon-phased studies

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Terminated(2)

Other(2)

Detailed Status

Completed5

Withdrawn2

unknown2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (44.4%)

Phase 23 (33.3%)

Phase 31 (11.1%)

N/A1 (11.1%)

Trials by Status

completed550%

withdrawn220%

unknown220%

recruiting110%

Recent Activity

1 active trials

Showing 5 of 10

recruitingphase_3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922

withdrawnphase_2

DAS181 for STOP COVID-19

NCT04354389

unknownphase_2

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

NCT04298060

unknown

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

NCT04460547

completednot_applicable

DAS181 for Severe COVID-19: Compassionate Use

NCT04324489

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03808922Phase 3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting

NCT04354389Phase 2

DAS181 for STOP COVID-19

Withdrawn

NCT04298060Phase 2

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

Unknown

NCT04460547

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

Unknown

NCT04324489Not Applicable

DAS181 for Severe COVID-19: Compassionate Use

Completed

NCT01441024Phase 2

DAS181 in Patients With Parainfluenza

Withdrawn

NCT00876161Phase 1

DAS181 Single Dose Escalation Study in Healthy Adults

Completed

NCT01651494Phase 1

Influenza Antiviral DAS-181-F04 in Healthy Adults

Completed

NCT01173224Phase 1

Influenza Antiviral DAS181-F03

Completed

NCT00527865Phase 1

Single Dose Escalating Study of DAS181 in Adults

Completed

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10